ClinicalTrials.gg
Active, not recruitingNCT06767345Updated Oct 26, 2026

Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization

A Phase 4 interventional study of Rosuvastatin and Rosuvastatin/ezetimibe in Coronary Artery Disease, Atherosclerosis of Coronary Artery and Plaque, Atherosclerotic, sponsored by Korea University Anam Hospital. Active, not recruiting at 7 sites in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Korea University Anam Hospital · Phase 4, Interventional, and Treatment

How we know

Updated Oct 26, 2026Now Active, not recruitingEnrollment updated+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
410
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 34 studies testing rosuvastatin in Coronary Artery Disease — 2 open to participants now, 5 under way, 1 of them phase 3. rosuvastatin · Coronary Artery Disease.

Enrollment
7th of 34
410 · median 175
Started
2025
with 1 other
Phase 4
22 of 34
none open now
Registered
33rd of 34
by date
Lead sponsor
3 of 34
Korea University Anam Hospital

Among the 34 studies testing rosuvastatin in Coronary Artery Disease, this one is the 7th largest by enrollment, is one of 2 that started in 2025, is one of 22 in phase 4, and was the 33rd registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

2 of the 34 studies testing rosuvastatin in Coronary Artery Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing rosuvastatin in Coronary Artery Disease, or all of them as a file.
02

Study summary

This study is a prospective, multicenter, randomized clinical trial aimed at comparing the effects of moderate-intensity statin plus ezetimibe combination therapy versus high-intensity statin monotherapy on coronary plaque stabilization. Using advanced imaging techniques such as near-infrared spectroscopy-intravascular ultrasound (NIRS-IVUS), the trial evaluates whether the combination therapy is non-inferior to monotherapy in stabilizing coronary plaques over 52 weeks. The primary endpoint is the change in percent atheroma volume (PAV) from baseline to week 52, assessed by grayscale IVUS. Secondary outcomes include changes in lipid core burden, inflammatory markers, and clinical events like myocardial infarction and ischemic stroke. Seven hospitals participated in the study. A total of 410 participants were enrolled at six sites; no participants were enrolled at Inje University Ilsan Paik Hospital. Follow-up is ongoing.

03

Conditions studied

  • Coronary Artery Disease
  • Atherosclerosis of Coronary Artery
  • Plaque, Atherosclerotic
04

Who can participate

The criteria were revised on the registry on Oct 6, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult men and women aged 18 years or older.
  • Patients with coronary artery disease undergoing a coronary intervention procedure using intravascular imaging.
  • At least one major native coronary artery ("target vessel") meeting all the following criteria for intracoronary imaging immediately following a qualifying PCI procedure:

    • Angiographic evidence of coronary artery stenosis ≥30% by angiographic visual estimation.
    • Target vessel is accessible to the imaging catheter and suitable for intracoronary imaging in the proximal 50 mm segment.
    • Target vessel is not a bypass graft (saphenous vein or arterial) or a bypassed graft vessel.
    • Target vessel has not undergone PCI within the target segment.
    • Target vessel is not a candidate for PCI at the time of the procedure or for 6 months thereafter (per investigator's judgment).
  • Patients who have provided written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Left main stem lesion: Left main coronary artery stenosis ≥50% by coronary angiographic visual estimation.
  • History of coronary artery bypass graft surgery (CABG).
  • Unstable clinical condition (hemodynamic or electrical instability).
  • Severe coronary artery calcification or tortuosity interfering with IVUS, NIRS, or evaluation.
  • Uncontrolled cardiac arrhythmia (recurrent and symptomatic ventricular tachycardia or atrial fibrillation with rapid ventricular response) not controlled by medication within 3 months prior to screening.
  • Active liver disease or liver dysfunction.
  • Severe renal dysfunction ( \<30 mL/min/1.73m²)
  • Known allergy to contrast media, heparin, aspirin, ticagrelor, or prasugrel.
  • Active infection or major hematologic, metabolic, or endocrine dysfunction as determined by the investigator.
  • Planned surgery within 12 months.
  • Currently enrolled in another randomized device study or a drug study involving lipid-lowering therapy.
  • Estimated of less than 2 years.
  • Women of (under 50 years of age) who:

    • Had their last menstrual period within the last 12 months.
    • Have not had tubal ligation, oophorectomy, or hysterectomy.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
410 participants (actual)

Study arms

  • Active comparator
    High Intensity Statin monotherapy

    Rosuvastatin 20 mg once daily

    Drug: Rosuvastatin

  • Experimental
    Combination therapy

    Rosuvastatin 10mg plus Ezetimibe 10mg fixed dose single-pill combination

    Drug: Rosuvastatin/ezetimibe

Interventions

06

What researchers measure

Primary outcomes

  1. Change in percent atheroma volume (PAV) from baseline to week 52, assessed by gray-scale IVUS

    Percent atheroma volume (PAV) is calculated within matched coronary-artery regions of interest as 100 × Σ(EEM CSA - lumen CSA)/Σ(EEM CSA), where EEM CSA is the external elastic membrane cross-sectional area and lumen CSA is the lumen cross-sectional area. Change in PAV between baseline and week 52 is assessed by gray-scale IVUS.

    Time frame: 52 weeks

Secondary outcomes

  1. Change from baseline to week 52 in total lipid core burden index measured by NIRS (LCBItotal)

    Time frame: 52 weeks

  2. Changes in NT-pro-BNP from baseline to 52 weeks and associations with plaque progression/regression indices

    Time frame: 52 weeks

  3. Changes in hsTnT from baseline to 52 weeks and associations with plaque progression/regression indices

    Time frame: 52 weeks

  4. Changes in hsCRP from baseline to 52 weeks and associations with plaque progression/regression indices

    Time frame: 52 weeks

  5. Cataract incidence from baseline to 52 weeks

    Time frame: 52 weeks

  6. Adherence from baseline to week 52 (80% or greater)

    Proportion of patients achieving ≥80% adherence to prescribed medication from baseline to week 52

    Time frame: 52 weeks

  7. Incidence of statin-associated muscle syndrome (SAMS) from baseline to week 52

    Time frame: 52 weeks

  8. Incidence of new diabetes from baseline to week 52

    Time frame: 52 weeks

  9. Ischemic Stroke/TIA from Baseline to Week 52

    Time frame: 52 weeks

  10. Ischemic Coronary Revascularization From Baseline to Week 52

    Time frame: 52 weeks

  11. Nonfatal myocardial infarction from baseline to week 52

    Time frame: 52 weeks

  12. Cardiac-related deaths from baseline to week 52

    Time frame: 52 weeks

  13. All deaths from baseline to week 52

    Time frame: 52 weeks

  14. Changes in LDL-cholesterol from baseline to 52 weeks and associations with plaque progression/regression indices

    LDL-cholesterol levels measured in mg/dL. Blood samples will be collected at baseline and after 52 weeks.

    Time frame: 52 weeks

  15. Change in maximum LCBI within a 4-mm bin measured by NIRS from baseline to week 52 (maxLCBI4mm)

    Time frame: 52 weeks

  16. Change in corrected total atherosclerotic plaque volume (NTAV) measured by IVUS from baseline to week 52

    Time frame: 52 weeks

07

Study locations

7 sites
08

References and documents

Publications

  • Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011 Jun 22;305(24):2556-64. doi: 10.1001/jama.2011.860. PubMed 21693744 ↗
  • Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010 Feb 27;375(9716):735-42. doi: 10.1016/S0140-6736(09)61965-6. Epub 2010 Feb 16. PubMed 20167359 ↗
  • Davis JW, Weller SC. Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients. BMJ Open. 2021 Jun 15;11(6):e043714. doi: 10.1136/bmjopen-2020-043714. PubMed 34130955 ↗
  • Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, Chaitman BR, Senior R, Lopez-Sendon J, Alexander KP, Lopes RD, Shaw LJ, Berger JS, Newman JD, Sidhu MS, Goodman SG, Ruzyllo W, Gosselin G, Maggioni AP, White HD, Bhargava B, Min JK, Mancini GBJ, Berman DS, Picard MH, Kwong RY, Ali ZA, Mark DB, Spertus JA, Krishnan MN, Elghamaz A, Moorthy N, Hueb WA, Demkow M, Mavromatis K, Bockeria O, Peteiro J, Miller TD, Szwed H, Doerr R, Keltai M, Selvanayagam JB, Steg PG, Held C, Kohsaka S, Mavromichalis S, Kirby R, Jeffries NO, Harrell FE Jr, Rockhold FW, Broderick S, Ferguson TB Jr, Williams DO, Harrington RA, Stone GW, Rosenberg Y; ISCHEMIA Research Group. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020 Apr 9;382(15):1395-1407. doi: 10.1056/NEJMoa1915922. Epub 2020 Mar 30. PubMed 32227755 ↗
  • Park SJ, Ahn JM, Kang DY, Yun SC, Ahn YK, Kim WJ, Nam CW, Jeong JO, Chae IH, Shiomi H, Kao HL, Hahn JY, Her SH, Lee BK, Ahn TH, Chang KY, Chae JK, Smyth D, Mintz GS, Stone GW, Park DW; PREVENT Investigators. Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial. Lancet. 2024 May 4;403(10438):1753-1765. doi: 10.1016/S0140-6736(24)00413-6. Epub 2024 Apr 8. PubMed 38604213 ↗
  • Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK, Heo JH, Rha SW, Cho YH, Lee SJ, Ahn CM, Kim JS, Ko YG, Choi D, Jang Y, Hong MK; RACING investigators. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022 Jul 30;400(10349):380-390. doi: 10.1016/S0140-6736(22)00916-3. Epub 2022 Jul 18. PubMed 35863366 ↗
  • Raber L, Ueki Y, Otsuka T, Losdat S, Haner JD, Lonborg J, Fahrni G, Iglesias JF, van Geuns RJ, Ondracek AS, Radu Juul Jensen MD, Zanchin C, Stortecky S, Spirk D, Siontis GCM, Saleh L, Matter CM, Daemen J, Mach F, Heg D, Windecker S, Engstrom T, Lang IM, Koskinas KC; PACMAN-AMI collaborators. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022 May 10;327(18):1771-1781. doi: 10.1001/jama.2022.5218. PubMed 35368058 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Nov 2027, 30 months after the start.

Of 181 non-industry phase 4 interventional studies under Coronary Artery Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 30 months is below that.

Counting every sponsor, half of 194 studies reached it within 35 months; a quarter within 20 and three quarters within 58.

Primary completion moved once since we started tracking on Sep 25, 2026: Jan 2028 → Nov 2027, on Oct 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2025
First posted
Jan 9, 2025
StartActual
May 12, 2025
Primary completionEst.
Nov 2027was Jan 2028
CompletionEst.
Jun 25, 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 6, 2026
Sites
6 sites added
Show 6 added (6 South Korea)
  • Inje University Ilsan Paik Hospital · Goyang, South Korea
  • Kyung Hee University Hospital · Seoul, South Korea
  • Hanyang University Hospital · Seoul, South Korea
  • Kyung Hee University Hospital at Gangdong · Seoul, South Korea
  • Chung-Ang University Hospital · Seoul, South Korea
  • Ajou University Hospital · Suwon, South Korea
Oct 6, 2026
Primary completion
Jan 25, 2028→Nov 2027
Oct 6, 2026
Enrollment
408→410
Oct 26, 2026
Eligibility
2 inclusion criteria edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedAdult men and women over the age ofaged 18 years or older.
  • EditedTarget vessel is not a bypass graft (aorticsaphenous vein or arterial) or a bypassed graft vessel.
Exclusion criteria
  • EditedCurrently enrolled in another investigationalrandomized device study or a drug study involving lipid-lowering therapy.
Oct 6, 2026
Interventions
Changed statins, ezetimibe→Rosuvastatin; Combination therapy→Rosuvastatin/ezetimibe
Oct 6, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • Editedpercentage changeChange in coronarypercent atheroma volume (PAV) by gray-scale IVUS from baseline to week 52., assessed by gray-scale IVUSTime frame: 52 weeks
Oct 6, 2026
Secondary outcomes
1 edited, 13 added, 13 removed
What changed in the outcomes
  • EditedChange from baseline to week 52 in total lipid core BMIburden index measured by NIRS (LCBItotal)Time frame: 52 weeks
  • AddedChanges in NT-pro-BNP from baseline to 52 weeks and associations with plaque progression/regression indicesTime frame: 52 weeks
  • AddedChanges in hsTnT from baseline to 52 weeks and associations with plaque progression/regression indicesTime frame: 52 weeks
  • AddedChanges in hsCRP from baseline to 52 weeks and associations with plaque progression/regression indicesTime frame: 52 weeks
  • AddedCataract incidence from baseline to 52 weeksTime frame: 52 weeks
  • AddedAdherence from baseline to week 52 (80% or greater)Time frame: 52 weeks
  • AddedIncidence of statin-associated muscle syndrome (SAMS) from baseline to week 52Time frame: 52 weeks
  • AddedIncidence of new diabetes from baseline to week 52Time frame: 52 weeks
  • AddedIschemic Stroke/TIA from Baseline to Week 52Time frame: 52 weeks
  • AddedIschemic Coronary Revascularization From Baseline to Week 52Time frame: 52 weeks
  • AddedNonfatal myocardial infarction from baseline to week 52Time frame: 52 weeks
  • AddedCardiac-related deaths from baseline to week 52Time frame: 52 weeks
  • AddedAll deaths from baseline to week 52Time frame: 52 weeks
  • AddedChanges in LDL-cholesterol from baseline to 52 weeks and associations with plaque progression/regression indicesTime frame: 52 weeks
  • Removedother outcomeChanges in LDL-cholesterol from baseline to 52 weeks and associations with plaque progression/regression indicesTime frame: 52 weeks
  • Removedother outcomeAll deaths from baseline to week 52Time frame: 52 weeks
  • Removedother outcomeCardiac-related deaths from baseline to week 52Time frame: 52 weeks
  • Removedother outcomeNonfatal myocardial infarction from baseline to week 52Time frame: 52 weeks
  • Removedother outcomeIschemic Coronary Revascularization From Baseline to Week 52Time frame: 52 weeks
  • Removedother outcomeIschemic Stroke/TIA from Baseline to Week 52Time frame: 52 weeks
  • Removedother outcomeIncidence of new diabetes from baseline to week 52Time frame: 52 weeks
  • Removedother outcomeIncidence of statin-associated muscle syndrome (SAMS) from baseline to week 52Time frame: 52 weeks
  • Removedother outcomeAdherence from baseline to week 52 (80% or greater)Time frame: 52 weeks
  • Removedother outcomeCataract incidence from baseline to 52 weeksTime frame: 52 weeks
  • Removedother outcomeChanges in hsCRP from baseline to 52 weeks and associations with plaque progression/regression indicesTime frame: 52 weeks
  • Removedother outcomeChanges in hsTnT from baseline to 52 weeks and associations with plaque progression/regression indicesTime frame: 52 weeks
  • Removedother outcomeChanges in NT-pro-BNP from baseline to 52 weeks and associations with plaque progression/regression indicesTime frame: 52 weeks
Oct 6, 2026
Show all 2 updates
  1. Oct 26, 2026
    Enrollment 408→410
    + 1 other change: description
  2. Oct 6, 2026
    Recruiting→Active, not recruiting
    6 sites added
    Show 6 added (6 South Korea)
    • Inje University Ilsan Paik Hospital · Goyang, South Korea
    • Kyung Hee University Hospital · Seoul, South Korea
    • Hanyang University Hospital · Seoul, South Korea
    • Kyung Hee University Hospital at Gangdong · Seoul, South Korea
    • Chung-Ang University Hospital · Seoul, South Korea
    • Ajou University Hospital · Suwon, South Korea
    Primary completion Jan 25, 2028→Nov 2027
    Eligibility 2 inclusion criteria edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedAdult men and women over the age ofaged 18 years or older.
    • EditedTarget vessel is not a bypass graft (aorticsaphenous vein or arterial) or a bypassed graft vessel.
    Exclusion criteria
    • EditedCurrently enrolled in another investigationalrandomized device study or a drug study involving lipid-lowering therapy.
    Primary outcomes 1 edited
    What changed in the outcomes
    • Editedpercentage changeChange in coronarypercent atheroma volume (PAV) by gray-scale IVUS from baseline to week 52., assessed by gray-scale IVUSTime frame: 52 weeks
    Secondary outcomes 1 edited, 13 added, 13 removed
    What changed in the outcomes
    • EditedChange from baseline to week 52 in total lipid core BMIburden index measured by NIRS (LCBItotal)Time frame: 52 weeks
    • AddedChanges in NT-pro-BNP from baseline to 52 weeks and associations with plaque progression/regression indicesTime frame: 52 weeks
    • AddedChanges in hsTnT from baseline to 52 weeks and associations with plaque progression/regression indicesTime frame: 52 weeks
    • AddedChanges in hsCRP from baseline to 52 weeks and associations with plaque progression/regression indicesTime frame: 52 weeks
    • AddedCataract incidence from baseline to 52 weeksTime frame: 52 weeks
    • AddedAdherence from baseline to week 52 (80% or greater)Time frame: 52 weeks
    • AddedIncidence of statin-associated muscle syndrome (SAMS) from baseline to week 52Time frame: 52 weeks
    • AddedIncidence of new diabetes from baseline to week 52Time frame: 52 weeks
    • AddedIschemic Stroke/TIA from Baseline to Week 52Time frame: 52 weeks
    • AddedIschemic Coronary Revascularization From Baseline to Week 52Time frame: 52 weeks
    • AddedNonfatal myocardial infarction from baseline to week 52Time frame: 52 weeks
    • AddedCardiac-related deaths from baseline to week 52Time frame: 52 weeks
    • AddedAll deaths from baseline to week 52Time frame: 52 weeks
    • AddedChanges in LDL-cholesterol from baseline to 52 weeks and associations with plaque progression/regression indicesTime frame: 52 weeks
    • Removedother outcomeChanges in LDL-cholesterol from baseline to 52 weeks and associations with plaque progression/regression indicesTime frame: 52 weeks
    • Removedother outcomeAll deaths from baseline to week 52Time frame: 52 weeks
    • Removedother outcomeCardiac-related deaths from baseline to week 52Time frame: 52 weeks
    • Removedother outcomeNonfatal myocardial infarction from baseline to week 52Time frame: 52 weeks
    • Removedother outcomeIschemic Coronary Revascularization From Baseline to Week 52Time frame: 52 weeks
    • Removedother outcomeIschemic Stroke/TIA from Baseline to Week 52Time frame: 52 weeks
    • Removedother outcomeIncidence of new diabetes from baseline to week 52Time frame: 52 weeks
    • Removedother outcomeIncidence of statin-associated muscle syndrome (SAMS) from baseline to week 52Time frame: 52 weeks
    • Removedother outcomeAdherence from baseline to week 52 (80% or greater)Time frame: 52 weeks
    • Removedother outcomeCataract incidence from baseline to 52 weeksTime frame: 52 weeks
    • Removedother outcomeChanges in hsCRP from baseline to 52 weeks and associations with plaque progression/regression indicesTime frame: 52 weeks
    • Removedother outcomeChanges in hsTnT from baseline to 52 weeks and associations with plaque progression/regression indicesTime frame: 52 weeks
    • Removedother outcomeChanges in NT-pro-BNP from baseline to 52 weeks and associations with plaque progression/regression indicesTime frame: 52 weeks
    Interventions Changed statins, ezetimibe→Rosuvastatin; Combination therapy→Rosuvastatin/ezetimibe
    + 5 other changes: index terms, verification date, description, contact details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06767345
Collaborators
Yuhan Corporation, Hanmi Pharmaceutical co., ltd.
Responsible party
Soon Jun Hong (Professor, Korea University Anam Hospital) — Principal investigator
First posted
Jan 9, 2025
Start date
May 12, 2025
Primary completion
Nov 2027 (estimated)
Completion
Jun 25, 2028 (estimated)
Last update
Oct 26, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosuvastatin · Ezetimibe

Start the discussion